Markets
Tendies
@tendies
Bought RNXT
Shares
down -17.86%
At 1.4, Exited 1.15
I've been keeping an eye on RNXT as it's pulling back to strong support around $1.30–$1.35. If the stock bounces at this level, it could be a solid bu...
Read
More
Thesis
I've been keeping an eye on RNXT as it's pulling back to strong support around $1.30–$1.35. If the stock bounces at this level, it could be a solid buy-the-dip opportunity since it remains above major moving averages. Just being cautious though, as a breakdown could lead to further downside.
Go back
Tendies
@tendies
Bought RNXT
Shares
up 11.61%
At 1.33, Exited 1.49
I'm really optimistic about RenovoRx right now due to its strong fundamentals and the promising potential of its TAMP technology. With FDA Orphan Drug...
Read
More
Thesis
I'm really optimistic about RenovoRx right now due to its strong fundamentals and the promising potential of its TAMP technology. With FDA Orphan Drug Designation and a wide market landscape, I see a significant opportunity for a price appreciation in both the short and long term.
Go back
Tendies
@tendies
Bought RNXT
Shares
up 16.53%
At 1.21, Exited 1.41
I've been closely following the breakthroughs in LAPC treatments, and RenovoCath's TAMP therapy with its impressive survival improvement and significa...
Read
More
Thesis
I've been closely following the breakthroughs in LAPC treatments, and RenovoCath's TAMP therapy with its impressive survival improvement and significant reduction in side effects really stands out to me. I think investing in RNXT could be a smart move as their approach might capture a growing market share in cancer treatment.
Go back
Tendies
@tendies
Bought RNXT
Shares
0.0%
At 1.27, Exited 1.27
I'm really optimistic about $RNXT given the promising prospects of their lead product and the pending FDA approvals. The potential for significant ROI...
Read
More
Thesis
I'm really optimistic about $RNXT given the promising prospects of their lead product and the pending FDA approvals. The potential for significant ROI seems promising, especially with their track record and innovative technology aimed at treating difficult cancers. This stock could really take off in the upcoming months.
Go back
Tendies
@tendies
Bought RNXT
Shares
up 10.12%
At 1.1, Exited 1.21
I believe $RNXT has great potential given its recent Q3 results, especially with the progress in their Phase III clinical trial and a promising low fl...
Read
More
Thesis
I believe $RNXT has great potential given its recent Q3 results, especially with the progress in their Phase III clinical trial and a promising low float. I'm confident that as trial catalysts and good news roll in, the stock will see a nice upward movement.
Go back
Tendies
@tendies
Bought RNXT
Shares
down -6.96%
At 1.15, Exited 1.07
I just bought some RNXT shares after seeing its strong recovery and positive technical indicators. The breakout above key resistance levels and increa...
Read
More
Thesis
I just bought some RNXT shares after seeing its strong recovery and positive technical indicators. The breakout above key resistance levels and increased trading volume suggest that this uptrend could continue, especially with growing demand for their RenovoCath system paving the way for future revenue growth.
Go back
Tendies
@tendies
Bought RNXT
Shares
down -0.93%
At 1.07, Exited 1.06
I believe $RNXT is poised for a bounce off the $1 support after its recent 24% surge. The strong volume on Friday and positive news about ongoing clin...
Read
More
Thesis
I believe $RNXT is poised for a bounce off the $1 support after its recent 24% surge. The strong volume on Friday and positive news about ongoing clinical trials indicate that this could be a great swing trade opportunity for recovery.
Go back
Tendies
@tendies
Bought RNXT
Shares
down -7.83%
At 1.15, Exited 1.06
With the positive early-stage clinical data showing significant improvement in overall survival for LAPC patients using the TAMP platform, RNXT is set...
Read
More
Thesis
With the positive early-stage clinical data showing significant improvement in overall survival for LAPC patients using the TAMP platform, RNXT is set to benefit as its Phase III trial progresses, making it a good swing trade opportunity.
Go back
